Antibody–drug conjugates come of age in oncology

Charles Dumontet, Janice M. Reichert, Peter D. Senter, John M. Lambert, Alain Beck

Abstract

Advances and challenges in antibody-drug conjugates (ADCs) for targeted cancer therapy Antibody–drug conjugates (ADCs) combine...

Published 04 November 2024

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models

Kamel Chettab, Chantel Fitzsimmons, Alexey Novikov, Morgane Denis, Capucine Phelip, Doriane Mathé, Pierre Antoine Choffour, Sabine Beaumel, Eric Fourmaux, Patrick Norca, David Kryza, Anne Evesque, Lars Petter Jordheim, Emeline Perrial, Eva-Laure Matera, Martine Caroff, Jerome Kerzerho, and Charles Dumontet

Abstract

fimmu-14-1066402

Published 08 June 2023

Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy

Morgane Denis, Doriane Mathe, Manon Micoud, Pierre-Antoine Choffour, Chloé Grasselly, Eva-Laure Matera, Charles Dumontet

Abstract

Introduction The discovery of immune checkpoint inhibitors (ICI) has deeply modified treatment in several cancer...

Published 24 May 2023

In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies

Morgane Denis, Chloe Grasselly, Pierre-Antoine Choffour, Anne Wierinckx, Doriane Mathe, Kamel Chettab, Anne Tourette, Nolan Talhi, Aurore Bourguignon, Fabian Birzele, Elsa Kress, Lars Petter Jordheim, Christian Klein, Eva-Laure Matera, Charles Dumontet

Abstract

ABSTRACT Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients...

Published 04 July 2022

How can immune checkpoint inhibitors cause hyperprogression in solid tumours?

Morgane Denis, Michaël Duruisseaux, Marie Brevet et Charles Dumontet

Abstract

INTRODUCTION Since approval by the Food and Drug Administration (FDA) in 2011 of the first...

Published 06 April 2020

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

Chloé Grasselly, Morgane Denis, Aurore Bourguignon, Nolan Talhi, Doriane Mathe, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera and Charles Dumontet

Abstract

INTRODUCTION Immune checkpoint inhibitors (ICI), such as anti-PD-1 (Programmed cell death 1) or anti-PD-L1 (Programmed...

Published 10 October 2018

Synthesis and Preclinical Evaluation of TPA-Based Zinc Chelators as Metallo-beta-lactamase Inhibitors

Christian Schnaars, Geir Kildahl-Andersen, Anthony Prandina, Roya Popal†, Sylvie Radix, Marc Le Borgne , Tor Gjøen, Adriana Magalhães Santos Andresen, Adam Heikal, Ole Andreas Økstad, Christopher Fröhlich, Ørjan Samuelsen, Silje Lauksund, Lars Petter Jordheim, Pål Rongved, and Ove Alexander Høgmoen Åstrand

Abstract

ABSTRACT: The rise of antimicrobial resistance (AMR) worldwide and the increasing spread of multi-drug-resistant organisms...

Published 01 October 2018

Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway

Juliette Sauveur, Eva-Laure Matera, Kamel Chettab, Philippe Valet, Jerome Guitton, Ariel Savina, and Charles Dumontet

Abstract

ABSTRACT Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that specifically targets HER2 thanks to its antibody...

Published 30 April 2018

Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies.

Duong, M. N., Matera, E., Mathe, D., Evesque, A., Valsesia-Wittmann, S., Clemenceau, B., and Dumontet, C

Abstract

Targeted therapies of malignancies currently consist of therapeutic monoclonal antibodies and small molecule kinase inhibitors....

Published 01 January 2018

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models

Herter, S., Herting, F., Mundigl, O., Waldhauer, I., Weinzierl, T., Fauti, T., Muth, G., Ziegler-Landesberger, D., Van Puijenbroek, E., Lang, S., Duong, M. N., Reslan, L., Gerdes, C. A., Friess, T., Baer, U., Burtscher, H., Weidner, M., Dumontet, C., Umana, P., Niederfellner, G., Bacac, M., and Klein, C

Abstract

Abstract We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab),...

Published 01 January 2018

Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868

Jordheim, L. P., Plesa, A., Dreano, M., Cros-Perrial, E., Keime, C., Herveau, S., Demangel, D., Vendrell, J. A., and Dumontet, C

Abstract

ABSTRACT Purpose: The need for new treatment options for acute myeloid leukemia (AML) is increasing....

Published 01 January 2018